ANIP news

ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, an increase of 27.6% year-over-year, alongside its strategic offer to acquire Egetis Therapeutics for market growth in rare diseases.

ANI Pharmaceuticals appointed Henry Gosebruch to its board to bolster business development capabilities amid its transformation into a Rare Disease company, while also announcing the resignation of board member Muthusamy Shanmugam.

AstroNova Inc. has entered into a merger agreement with Orion Merger Parent, Inc. and Orion MergerCo X, Inc., dated June 16, 2026. The transaction represents a significant corporate action that will result in AstroNova becoming a subsidiary of the Orion entities.